Stock Traders Purchase Large Volume of Call Options on COMPASS Pathways (NASDAQ:CMPS)

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) saw unusually large options trading activity on Monday. Traders acquired 5,261 call options on the company. This is an increase of 420% compared to the typical daily volume of 1,012 call options.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CMPS. HC Wainwright reiterated a "buy" rating and set a $45.00 price objective on shares of COMPASS Pathways in a report on Monday, May 12th. Stifel Nicolaus assumed coverage on COMPASS Pathways in a research report on Thursday, February 27th. They set a "buy" rating and a $11.00 price target on the stock. Evercore ISI reiterated an "in-line" rating and issued a $6.00 target price (down from $11.00) on shares of COMPASS Pathways in a research note on Monday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $12.00 price target on shares of COMPASS Pathways in a report on Tuesday, May 27th. Finally, Canaccord Genuity Group dropped their target price on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $17.00.

COMPASS Pathways Trading Down 47.6%

Shares of CMPS traded down $2.21 during midday trading on Monday, hitting $2.43. 14,633,403 shares of the stock were exchanged, compared to its average volume of 991,696. COMPASS Pathways has a 52-week low of $2.37 and a 52-week high of $8.54. The stock has a fifty day simple moving average of $4.09 and a 200 day simple moving average of $3.89. The firm has a market cap of $226.88 million, a P/E ratio of -1.22 and a beta of 2.25. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.18 and a current ratio of 10.18.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.03. On average, research analysts anticipate that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

Institutional Investors Weigh In On COMPASS Pathways

Several institutional investors have recently added to or reduced their stakes in the business. Cerity Partners LLC acquired a new stake in COMPASS Pathways during the 1st quarter worth $29,000. GAMMA Investing LLC increased its holdings in COMPASS Pathways by 93.6% during the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after acquiring an additional 5,003 shares in the last quarter. Ethos Financial Group LLC purchased a new stake in COMPASS Pathways in the 1st quarter valued at approximately $35,000. Flagship Harbor Advisors LLC boosted its position in COMPASS Pathways by 27.7% during the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock worth $41,000 after acquiring an additional 3,134 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in shares of COMPASS Pathways during the first quarter worth $41,000. Hedge funds and other institutional investors own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.